Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
about
Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderLong-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment.Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian womenEvidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.Current pharmacotherapeutic strategies for overactive bladder.Clinical pharmacology of old age syndromesMuscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderTolterodine for the treatment of overactive bladder: a review.The emergence of new drugs for overactive bladder.Prevalence, management and outcomes of medically complex vulnerable elderly patients with urinary incontinence in the United States.Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature.Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder.Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.The efficacy of resiniferatoxin in prevention of catheter related bladder discomfort in patients after TURP - a pilot, randomized, open studyA prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients.Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years.
P2860
Q28275473-B7759F2B-E88C-46A9-A4E2-DA432FDF6A7CQ30410914-2DB92296-3E68-42B8-8017-136330BDB7C8Q33783024-EDFE34BB-34F5-4E2E-86CA-4CF870FC61A6Q34515443-EABC18CB-A109-470A-B3E3-5ADAD2F58B75Q34706864-ED055006-EBEE-417E-964F-0BDC08789129Q35200049-BE748D31-2F35-47C9-A567-3011A4D97D52Q35546189-3BF0E207-B90B-4E51-86AC-C99CFDB2D33AQ36150735-85651415-A605-451C-BE40-589C3EB1F93AQ36407417-51B98F2C-6057-487D-AD11-4EC7BF46D118Q37308649-C93287D1-EDC7-43B9-A3A4-5A2EFFA4A352Q37864717-D823DCDD-1A89-4FA3-ABD2-7EAE2858BAACQ37914849-6B7E66E7-ECB2-483D-BE88-59093CF35D9CQ38190923-EEE19662-CF66-448F-BDC3-B9CE99E26D93Q41774563-E4B8D071-23D5-4D54-8365-7D92CD26274CQ43109559-9440B09B-536C-4DDB-9E66-202BA6463DD7Q44004623-BA1BC3A0-51DB-4B75-BB10-5FC36EAEA9C9Q44426277-30909D59-785D-4A07-8500-2A013C153D19
P2860
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@en
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@nl
type
label
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@en
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@nl
prefLabel
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@en
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@nl
P2093
P356
P1476
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine.
@en
P2093
P2888
P304
P356
10.1007/PL00007094
P577
2001-04-01T00:00:00Z
P6179
1023360288